Spyre Therapeutics Newsroom

Spyre Therapeutics Is Maintained at Buy by Guggenheim

Dow JonesOct 26 03:42 · Ratings

Spyre Therapeutics Analyst Ratings

BenzingaOct 26 03:31 · Ratings

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 22 05:31 · Ratings

Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 17 23:31 · Ratings

Spyre Therapeutics Advances SPY003 for IBD Treatment

TipRanksOct 15 18:52

Paragon Therapeutics Granted Spyre Therapeutics An Exclusive License To Develop, Manufacture, And Commercialize Certain Antibodies And Products Targeting IL-23 For Irritable Bowel Disease, Paragon Will Receive $22M As Milestone Payments And Further...

BenzingaOct 15 18:41

Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating

TipRanksOct 15 18:15 · Ratings

Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40

Futu NewsOct 15 17:34 · Ratings

Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)

TipRanksOct 15 17:07 · Ratings

Express News | Spyre Therapeutics Inc : Jefferies Raises Target Price to $37 From $31

BreakingsOct 15 11:30

Express News | Spyre Therapeutics Inc: Spy003 First-in-Human Dosing Now Expected Q1 2025

BreakingsOct 14 20:01

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW Supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

PR NewswireOct 14 20:00

Spyre Therapeutics Announces Grants of Inducement Awards

PR NewswireOct 5 05:00

Express News | Spyre Therapeutics Appoints DR. Sheldon Sloan as Chief Medical Officer

BreakingsOct 1 20:00

Press Release: Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Dow JonesOct 1 20:00

BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40

Futu NewsSep 25 18:31 · Ratings

Spyre Therapeutics Poised for Market Leadership With Promising IBD Drug Candidates

TipRanksSep 25 18:27

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50

LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.5%

Futu NewsSep 24 20:31 · Ratings

Spyre Therapeutics to Participate in Upcoming Investor Conference

PR NewswireSep 11 04:47

Spyre Therapeutics Files for $500M Mixed Securities Shelf

Seeking AlphaSep 7 04:26